



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/206,249	12/07/1998	MIRI SEIBERG	JBP438	5255
<div>7590 12/14/2007 PHILIP S. JOHNSON, ESQ. JOHNSON &amp; JOHNSON ONE JOHNSON &amp; JOHNSON PLAZA NEW BRUNSWICK, NJ 08933-7003</div>			<div>EXAMINER MELLER, MICHAEL V</div>	
			<div>ART UNIT 1655</div>	<div>PAPER NUMBER</div>
			<div>MAIL DATE 12/14/2007</div>	<div>DELIVERY MODE PAPER</div>

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

# Office Action Summary

Application No.

09/206,249

Applicant(s)

SEIBERG ET AL.

Examiner

Michael V. Meller

Art Unit

1655

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 21 September 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 75-84 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 75-84 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

## Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

**DETAILED ACTION**

***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 75-84 are rejected under 35 U.S.C. 102 (b) as being anticipated by JP 408143442 (see the entire translation supplied by applicant especially the claims, paragraph 8, abstract).

JP '442 teaches a water extract of soybeans used to treat eczema. Whole soybeans are ground and water is added and then the extract is filtered. The ground matter is heated but to a temperature which could read on 5 °C.

Applicant argues that JP '442 does not teach that the soybean in JP '442 was crushed or broken but if one looks at page 3, claim 6 of the translation of JP '442, it is clear that the soybeans were ground which would crush the soybean and that the soybean was heated anywhere from 5-100 °C. Thus, it could have been heated to only 5 °C which would have not denatured the protein.

Applicant argues in the response filed 9/21/2007 that the '442 publication clearly indicates that proteins are undesirable in the elute product and that the authors of the reference seek to reduce substantially or eliminate their presence in the elute, but this is only one possibility and the reference clearly teaches other temperatures such as mentioned above, i.e. 5 °C, not at just 20-30 °C.

Applicant next argues that at page 2 of the translation of '442 it is taught that the soybeans are not crushed and the liquid from the uncrushed soybeans is not likely to contain STI since (as applicant argues) STI cannot diffuse from the uncrushed soybeans or dehulled soybeans. First of all applicant has provided not evidence of this alleged fact. Secondly, assuming applicant is right (which the examiner is not saying that applicant is) the STI would still be in the extract thus reading on the claims, since the STI was not diffused as applicant has argued.

Claims 75-84 are rejected under 35 U.S.C. 102 (a) as being anticipated by JP 410226642 (abstract).

JP '642 teaches an extract of soybeans used to treat psoriasis. The extract can be applied in an ointment form, see abstract.

Applicant argues that the genistein has to be denatured in order to be ingested by humans but upon closer inspection of JP '642 it is clear that the extract is applied topically, i.e. as an ointment. Thus, it does not have to be ingested by humans as applicants argue.

Applicant argues in their response filed 9/21/2007, that "pure genistein" does not contain STI. While this is not agreed with, applicant provides no evidence of this allegation. Further, applicant presents US Patent 5141746 as evidence that genistein is extracted commonly with organic solvents. While this is noted, this patent only shows one particular method of extracting genistein and this still does not prove applicant's allegation. Further, JP '642 refers to "pure genistein" in the context that the soybean product which can have a low concentration is usable in place of pure genistein. Thus, not only is the reference not teaching pure genistein As alleged by applicants it is even promoting the use of a "low concentration product" as being as good as the "pure genistein" thus making applicant's arguments moot.

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael V. Meller whose telephone number is 571-272-0967. The examiner can normally be reached on Monday thru Thursday: 9:30am-6:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on 571-272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number:  
09/206,249  
Art Unit: 1655

Page 6

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

A handwritten signature in black ink, appearing to read 'M. Meller', followed by a long horizontal line extending to the right.

Michael V. Meller  
Primary Examiner  
Art Unit 1655